Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve 1. Audited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has informed BSE that its Board of Directors will meet on 30 May 2025 at the registered office. The key agenda items are to consider and approve the audited financial results and the audit report for the quarter and full year ended 31 March 2025. The signed intimation was filed by Mr. Dhananjaya Alli, Executive Director (DIN: 00610909). This is a standard SEBI Listing Obligations disclosure (Regulation 29) ahead of the results announcement.
No immediate impact on shareholders — this is purely a procedural notice confirming an upcoming results announcement. Investors should watch for the actual audited numbers to be published after 30 May 2025, which could move the stock depending on performance versus expectations.